Show simple item record

dc.contributor.authorGuglielmetti, L
dc.contributor.authorHewison, C
dc.contributor.authorAvaliani, Z
dc.contributor.authorHughes, J
dc.contributor.authorKiria, N
dc.contributor.authorLomtadze, N
dc.contributor.authorNdjeka, N
dc.contributor.authorSetkina, S
dc.contributor.authorShabangu, A
dc.contributor.authorSikhondze, W
dc.contributor.authorSkrahina, A
dc.contributor.authorVeziris, N
dc.contributor.authorFurin, J
dc.date.accessioned2017-02-28T21:31:58Z
dc.date.available2017-02-28T21:31:58Z
dc.date.issued2017-02-01
dc.date.submitted2017-02-27
dc.identifier.citationExamples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries. 2017, 21 (2):167-174 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920
dc.identifier.pmid28234080
dc.identifier.doi10.5588/ijtld.16.0493
dc.identifier.urihttp://hdl.handle.net/10144/618813
dc.descriptionAbstract available only, full article is not open access. To access this article click on "additional links".en
dc.description.abstractFor the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/28234080en
dc.rightsArchived with thanks to The international Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Diseaseen
dc.titleExamples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countriesen
dc.identifier.journalThe International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Diseaseen
html.description.abstractFor the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.


This item appears in the following Collection(s)

Show simple item record